Get the Stockscreener App
8.53
1.31%
0.11
After Hours:
8.34
-0.19
-2.23%
Ventyx Biosciences Inc stock is traded at $8.53, with a volume of 5.41M.
It is up +1.31% in the last 24 hours and up +174.28% over the past month.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
See More
Previous Close:
$8.42
Open:
$8.42
24h Volume:
5.41M
Relative Volume:
1.63
Market Cap:
$608.26M
Revenue:
-
Net Income/Loss:
$-192.96M
P/E Ratio:
-2.5848
EPS:
-3.3
Net Cash Flow:
$-167.04M
1W Performance:
+46.82%
1M Performance:
+174.28%
6M Performance:
+541.35%
1Y Performance:
+294.91%
1-Day Range:
$8.10
$9.50
1-Week Range:
$5.78
$9.50
52-Week Range:
$0.783
$9.50
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Name
Ventyx Biosciences Inc
Sector
Industry
Phone
(858) 945-2393
Address
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Compare VTYX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
8.53 | 600.42M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Mar-12-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-07-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-07-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-07-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-07-23 | Downgrade | Stifel | Buy → Hold |
| Nov-07-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Wells Fargo | Overweight |
| Dec-19-22 | Initiated | Goldman | Buy |
| Nov-17-22 | Initiated | Morgan Stanley | Overweight |
| Sep-07-22 | Initiated | Stifel | Buy |
| Sep-01-22 | Initiated | H.C. Wainwright | Buy |
| May-09-22 | Initiated | Credit Suisse | Outperform |
| Mar-31-22 | Initiated | Canaccord Genuity | Buy |
| Feb-01-22 | Initiated | Oppenheimer | Outperform |
| Nov-15-21 | Initiated | Jefferies | Buy |
| Nov-15-21 | Initiated | Piper Sandler | Overweight |
View All
Ventyx Biosciences Inc Stock (VTYX) Latest News
Why Ventyx Biosciences Inc. is moving todayAnalyst Downgrade & Safe Swing Trade Setup Alerts - newser.com
Is Ventyx Biosciences Inc. still worth holding after the dipPortfolio Gains Summary & Daily Chart Pattern Signals - newser.com
Market reaction to Ventyx Biosciences Inc.’s recent newsWeekly Trade Summary & Low Drawdown Investment Strategies - newser.com
Ashton Thomas Private Wealth LLC Takes Position in Ventyx Biosciences, Inc. $VTYX - MarketBeat
Has Ventyx Biosciences Inc. formed a bullish divergenceMarket Performance Recap & Capital Efficient Trade Techniques - newser.com
Applying Elliott Wave Theory to Ventyx Biosciences Inc.2025 Macro Impact & Daily Stock Momentum Reports - newser.com
Will Ventyx Biosciences Inc. stock split again soonJuly 2025 Decliners & Precise Entry and Exit Recommendations - newser.com
Ventyx Biosciences, Inc. (VTYX) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Is Ventyx Biosciences Inc. stock supported by innovation pipeline2025 Volatility Report & Weekly Top Gainers Trade List - newser.com
Will Ventyx Biosciences Inc. see short term momentumWeekly Trend Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Technical signs of recovery in Ventyx Biosciences Inc.July 2025 Price Swings & Weekly Hot Stock Watchlists - newser.com
Ventyx Biosciences Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
Ventyx Biosciences (NASDAQ:VTYX) Hits New 1-Year HighHere's Why - MarketBeat
Is Ventyx Biosciences Inc. stock attractive for growth ETFsCPI Data & Accurate Entry and Exit Point Alerts - newser.com
How to recover losses in Ventyx Biosciences Inc. stock2025 Volatility Report & Verified Entry Point Detection - newser.com
Will Ventyx Biosciences Inc. stock benefit from infrastructure spendingJuly 2025 Selloffs & Expert-Curated Trade Recommendations - newser.com
Biotech Stocks Hit 52-Week Highs: MTSR, INSM, ABVX, MAZE Lead October 30 Surge - RTTNews
Will Ventyx Biosciences Inc. stock see PE expansion2025 Support & Resistance & Safe Entry Trade Signal Reports - newser.com
Ventyx Biosciences (VTYX) Price Target Increased by 10.39% to 12.39 - MSN
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Sees Significant Decline in Short Interest - MarketBeat
Ventyx Biosciences (VTYX) to Release Earnings on Thursday - MarketBeat
Ventyx Biosciences (NASDAQ:VTYX) Stock Price Up 9.2% Following Analyst Upgrade - MarketBeat
Can Ventyx Biosciences Inc. stock double in next 5 yearsQuarterly Investment Review & AI Forecasted Stock Moves - newser.com
How Ventyx Biosciences Inc. stock reacts to global recession fears2025 Valuation Update & Safe Entry Zone Tips - fcp.pa.gov.br
Ventyx Biosciences Inc Stock (VTYX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.62%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):